BiologicalDrug
Benralizumab clinical trials
Also written Fasenra and MEDI-563.
- studies test it
- 68
- open now
- 6
- in phase 3
- 35
- first study started
- 2006
Keep track of what changes. Save the benralizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Fasenra
- 13
Studies by the year they started
67 studies that test it; most in 2019 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 6 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 19
- Phase 3
- 35
- Phase 4
- 11
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 32
Who runs them
Industry 46 · Other 22
AstraZeneca (38) · MedImmune LLC (6) · McMaster University (2) · Kyowa Kirin Co., Ltd. (2) · Dr. Grace Parraga (1) · Memorial Sloan Kettering Cancer Center (1) · Humanitas Clinical and Research Center (1) · NHS Greater Glasgow and Clyde (1)
Often tested with
Tested in the same studies.
Hyperpolarized Xe-129 (1) · Dupilumab (1) · Prednisolone (1)
Studies
Open first, then newest update. How each study uses benralizumab is read from its arms, and is right about nine times in ten.
Testing it · 68
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentRecruitingPhase 3AstraZenecaNCT07444567Written as Benralizumab
- A Trial to Investigate Benralizumab in Children With Eosinophilic DiseasesRecruitingPhase 3AstraZenecaNCT06512883Written as Benralizumab
- Fasenra: An Asthma StudyEnrolling by invitationPhase 4Endeavor HealthNCT07654842Written as Benralizumab
- Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)Not yet recruitingPhase 2University Hospital, LilleNCT06734884Written as Benralizumab 30 MG/ML [Fasenra]
- Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and EndotypingRecruitingPhase 4University of California, San DiegoNCT06385236Written as Benralizumab
- BenRalizumab Effect on Airway Remodeling in Severe asTHmaRecruitingPhase 4Aristotle University Of ThessalonikiNCT06288516Written as Benralizumab 30 mg/ml
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentCompletedPhase 3AstraZenecaNCT06750289Written as benralizumab
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaActive, not recruitingPhase 3AstraZenecaNCT05692180Written as Benralizumab
- Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsActive, not recruitingPhase 4AstraZenecaNCT03953300Written as Benralizumab
- STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaCompletedPhase 3AstraZenecaNCT06465485Written as Benralizumab
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.Active, not recruitingPhase 3AstraZenecaNCT04157348Written as Benralizumab
- A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)Active, not recruitingPhase 3AstraZenecaNCT04191304Written as Benralizumab
- Study of Benralizumab in People With Skin Side Effects Caused by Cancer TherapiesCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT04552288Written as Benralizumab
- Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)TerminatedPhase 3AstraZenecaNCT04157335Written as Benralizumab 30 mg
- Effect of Benralizumab in Atopic DermatitisCompletedPhase 2McMaster UniversityNCT03563066Written as Benralizumab
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsCompletedPhase 3AstraZenecaNCT04053634Written as Benralizumab
- Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRIActive, not recruitingNot applicableDr. Grace ParragaNCT03733535Written as Benralizumab
- Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis BronchiectasisTerminatedPhase 3AstraZenecaNCT05006573Written as Benralizumab
- Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)TerminatedPhase 3AstraZenecaNCT05251909Written as Benralizumab
- BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory ImagingCompletedPhase 4AstraZenecaNCT05552508Written as Benralizumab
See all 68 studies that test benralizumab →
Given in every arm · 1 — benralizumab is usual care beside what is tested
As the comparator · 1 — what is tested is compared with benralizumab
Codes
What other systems call benralizumab · ClinicalTrials.gg INT006028
- MeSH (NLM) C571386benralizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 71492GE1FXBENRALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1989100Confirmed FDA, Wikidata
- Wikidata Q3638304benralizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88594BenralizumabOne source FDA
- DrugBank DB12023One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571386 | benralizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 71492GE1FX | BENRALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1989100 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3638304 | benralizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88594 | Benralizumab | One source FDA |
| DrugBank | DB12023 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.